IMMIOS b.v.

Over IMMIOS b.v.

IIMMIOS is a pre-clinical stage company developing IMS-2407 antibody to reset tissue auto-immune disease providing durable relapse-free benefit to patients suffering from auto-immune and inflammatory disease. Our lead program is set-up to file IND/CTA YE 2026 and deliver proof of mechanism in patients (in two indications) in 2028. Portfolio development is ongoing to identify second program following IMS-2407. #autoimmune disease #antibody development #Series A fundraise #immune reset

Adres

• Hoofdkantoor

  Kloosterstraat 95349AB OssNoord-Brabant, Nederland

Team per functiegebied

Gebaseerd op 17 openbare functieprofielen, stand van 3 september 2026.

• Research / R&D12
• Other / Unclassifiable2
• Executive / C-Suite1
• Founder / Owner1
• Manufacturing / Production1